THE INTEREST OF BIOCHEMICAL MARKERS OF BONE TURNOVER FOR MONITORING TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Vol. 86 No. 2 (2008): Issue Feb 2008

##plugins.themes.academic_pro.article.main##

Eya Kalaï
Service de Biochimie Clinique Hôpital Charles Nicolle Tunis
Afef Bahlous
Department of Biochemistry Charles Nicolle Hospital - Tunis
Abdelaziz Makdouli
Service de Biochimie Clinique Hôpital Charles Nicolle Tunis
Hella Sahli
Service de Rhumatologie Hôpital La Rabta Tunis
Anis Klouz
National centre of Pharacovigilance - Tunisia
Mohamed Lakhal
National centre of Pharacovigilance - Tunisia
Jouda Abdelmoula
Service de Biochimie Clinique Hôpital Charles Nicolle Tunis

Abstract

Background : Postmenopausal osteoporosis is especially female pathology, whose incidence increases with age.
Aim : The purposes of this study are to evaluate the level of bone turnover by the determination of markers of bone formation (PAL, BAP) and marker of bone resorption (CTX) in the osteoporotic women, to study the correlations between bone biochemical markers, clinical parameters and radiological measurements and to assess the interest of biochemical markers in therapeutic monitoring after 6 months of antiresorptive treatment.
Methods : The authors report a prospective study of 134 osteoporotic women classified in two groups according to the presence of osteoporotic fracture. Patients of the first group G1 (n=102) with fractures, were treated by the bisphosphonates (risedronate), whereas the ones of the second group G2 (n=32) without fractures, were submited to calcic supplementation and vitamin D.
Results : The analyses showed that the femoral and lumbar BMD were statistically lower in the presence of osteoporotic fractures. However, the values of CTX were statistically higher in the patients of G1 group compared to those of the G2 group (0,708 ± 0,332 ng/ml versus 0,514 ± 0,225 ng/ml). The CTX were statistically correlated with the femoral and lumbar BMD (r = -0,21, p<0,05 and r = -0,348, p<0,001). The hypovitminosis were observed in 50,98% (52/102) of women with ostéoporotic fractures, whereas it was only 25% (8/32) in women without fractures. After 6 months of treatment by the bisphosphonates, the PAL, the BAP and the CTX have decreased with an average of, respectively, 19%, 46,5% and 62,9%. These variations were significantly more important in G1 group.
Conclusion : Tthe biochemical markers of bone turnover, in particular those of the resorption (CTX), can predict the postmenopausal woman’s bone loss evaluated by BMD, the risk of fractures and the efficiency of the bone treatments.

Keywords:

Osteoporosis, Serum CTX, Bone alkaline phosphatase, Bone mineral density, Bisphosphonate

##plugins.themes.academic_pro.article.details##

References

  1. Melton LJ 3rd, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989 ; 129 : 1000-11.
  2. Chavasseiux P, Meunier PJ. Mécanisme de la perte osseuse dans les ostéoporoses. Rev Prat 1995 ; 45 : 1083-8.
  3. Honkanen RJ, Honkanen K, Kroger H, Alhava E, Tuppurainen M, Saarikoski S. Risk factors of perimenopausal distal forearm fracture. Osteoporos Int 2000 ; 11 : 265-70.
  4. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. BMJ 1991 ; 303 : 961-4.
  5. Roux C. Méthodes de mesure de la densité osseuse et application à l'évaluation du risque ostéoporotique en pratique clinique. Ann Med Interne 2000 ; 151 : 385-91.
  6. Cummings SR, Black DM, Nevitt MC. Bone density at various sites for prediction of hip fractures. Lancet 1993 ; 341 : 72-5.
  7. Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997 ; 12 : 59-65.
  8. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turover, endogenous hormones and the risk of fractures in postmenopausal women: the OFFLY study. J Bone Miner Res 2000 ; 15 : 1526-36.
  9. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 2000 ; 283 :1425-6.
  10. Isaia G, Giorgiono R, Rini G.B, Bevilacqua M, Maugeri D, Adami S. Prevalence of hypovitaminosis D in elderly women in Italy. Osteoporos Int. 2003 ;14 : 577-82.
  11. Nuti R, Martini G, Valenti R, Gambera D, Gennari L, Salvadori S, et al. Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res 2004 ; 422 : 201-13.
  12. Seton M, Jackson V, Lasser K.E, Doppelt S, Pierre-Jacques M, Connelly M. Low 25-hydroxyvitamin D and osteopenia are prevalent in persons > or = 55 yr with fracture at any site : a prospective, observational study of persons fracturing in the communit
  13. Akkesson K, Kakönen SM, Karlsson M. Fracture induces long-term effects on bone turnover in humans. J Bone Miner Res 1999 ; 14.
  14. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women : the EPIDOS Study. J Bone Miner Res 1996 ; 11 : 1531-8.
  15. Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, et al. Matrix delivery transdermal 17-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int 1999 ; 9 : 358-66.
  16. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int, 2000 ; 8 (suppl 1) : S66-S76.
  17. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparaison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994 ; 79 : 1693-700.
  18. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 ; 87 : 4528- 35.
  19. Chailurkit L, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R. Biochemical markers of bone mineral density to intervention in early postmenopausal women: An experience in a clinical laboratory. Clin Chem 2001 ; 47 : 1083-8.
  20. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, et al. Intravenous ibandronate injections given every three months : a new treatment option to prevent bone loss in postmenopausal women. Ann Rheu Dis 2003 ; 62 : 969-75.
  21. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA et al. The efficacy and tolerability of risedronate once week for the treatment of postmenopausal osteoporosis. Calcif Tissue int 2002 ; 71 : 103-11.
  22. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000 ; 11 : 2
  23. Ravn P, Clemmesen B, Christiansen C. Biochemical makers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999 ; 24 : 237-44.
  24. Ravn P, Hosking D, Thompson D, Cizza G, Wasnish RD, McCLung M et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999 ;